舍巴医疗中心

Objective: Children who are hospitalized in a child psychiatry inpatient ward are frequently treated with anti-psychotic medications and are also characterized by being overweight. In this study, we aimed to investigate the ramifications of a customized dietary plan on weight percentile shifts in children hospitalized in an inpatient psychiatric ward. Methods: We retrospectively analyzed 42 children, age 6 to12 years admitted to a child psychiatry inpatient ward (from July 21 to February 23), with hospital stays ranging from 46 to 259 days. A clinical dietitian customized a general and personalized dietary plan composed of five meals per day and a plan for diet on weekend vacations. We measured the weight percentile weekly during the first 4 weeks and then once a month. A total of 7 measurements were taken and children underwent a minimum of four out of seven measurements. Results: Baseline median weight percentile was 86.5 (range 7-100) and blood metabolic measures were within the normal range both at admission and discharge. Of the total sample, 93% of children received anti-psychotics and 55% were on stimulants. A significant weight percentile decline was noted already after 4 weeks. Higher initial weight percentile and treatment with stimulants (especially males) predicted a more robust reduction in weight percentile over time. Conclusion: Customized dietary plan led to a noticeable drop in children's weight percentile in a child psychiatry inpatient ward. This underscores the importance of personalized dietary interventions during psychiatric hospitalizations of children. (c) 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Higher chronic physical morbidity has been reported in Holocaust survivors. Despite evidence of potential intergenerational effects, data on their offspring’s physical health remain limited. This exploratory study aimed to compare outcomes of cancer, diabetes, stroke, end-stage renal disease, bariatric surgery utilization, multi-morbidity, and mortality between offspring of female child Holocaust survivors and their counterparts, using national registry data. This cohort study compared offspring (born 1960–1990) of Jewish female Holocaust survivors born during 1940–1945 in European countries that were under the Nazi regime (exposed) and same-age offspring of same-age European-origin Jewish women unexposed to the Holocaust. The dataset was cross-linked with national disease, procedure, and mortality registries. Multivariable logistic regression and proportional hazards models were adjusted for birth cohort and sex. Exposed individuals (N = 20,193; 51

Abstract Background Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant myopathy, caused by a (GCN)n/polyalanine repeat expansion in the PABPN1 gene. In Israel, OPMD is particularly prevalent among individuals of Jewish Bukharian descent due to a (GCN)13 repeat expansion. In this retrospective study, we collected genetic and clinical data of OPMD patients who visited the Israeli reference clinic from its opening in 2022 through September 2025 and were enrolled in the Israeli OPMD registry (IsrO-PMD). Results A total of 102 Jewish individuals with OPMD symptoms and a confirmed molecular diagnosis were identified (52 males, 51.0%). The heterozygous (GCN)13 repeat allele (10/13 genotype) was found in 95 patients (93.1%), of whom 89 (93.7%) were of Bukharian descent, five (5.6%) were of Bulgarian origin, and a single patient was from Georgia. In this 10/13 genotype group (n = 95), initial symptoms were dysphagia and ptosis, which occurred at a similar mean age of 53.0 ± 8.3 and 53.9 ± 7.2 years, respectively. Symptoms of limb muscle weakness occurred significantly later, at a mean age of 57.9 ± 10.2 years. Overall, the onset of symptoms occurred approximately 4 years earlier in females (48.9 ± 7.9, n = 48) than in males (52.6 ± 7.1, n = 47), and this difference was statistically significant (p = 0.02). However, the difference did not reach significance when calculated for each of the three symptoms separately. On evaluation, at a mean age of 61.6 ± 10.7 years, dysphagia was present in 92/95 (96.8%) of patients, ptosis in 85/95 (89.5%), and limb muscle weakness in 56/95 (58.9%) of cases, most notably of hip flexion and abduction. Different genotypes were detected in seven patients: Three of Bukharian descent were homozygous for (GCN)13 repeats, three of Karaite descent were homozygous for (GCN)11 repeats, and one of Tunisian origion was heterozygous for (GCN)15 repeats (10/15 genotype). Discussion While most OPMD patients in Israel are of Jewish Bukharian descent, patients from other origins were also identified. Dysphagia and ptosis are the common initial symptoms, and overall, the onset of symptoms was reportedly earlier in females. Proximal muscle weakness becomes common with disease progression. Further studies are required to delineate genotype-phenotype correlations.

Foslevodopa/foscarbidopa (LDp/CDp) is a nonsurgical 24-h continuous subcutaneous infusion for patients with advanced Parkinson’s disease (aPD) and motor fluctuations uncontrolled on oral medications. We present the first multicountry real-world data from routine clinical practice. ROSSINI (NCT06107426) is an ongoing 3-year multicountry, prospective, observational study of adults with aPD who are LDp/CDp-naïve (cohort A) or transitioning from LDp/CDp open-label extension studies (NCT04379050/NCT04750226, cohort B). For this interim analysis, the primary endpoint was change from baseline to 6 months in OFF time [Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part IV (MDS-UPDRS-IV) modified item 4.3]. Safety was assessed by monitoring adverse events (AEs). Interim results for 105 cohort A patients enrolled ≥ 6 months by March 24, 2025 are presented only; cohort B results were limited (n = 5). Mixed-effects models for repeated measurements (continuous outcomes) were utilized, adjusted for country. Cohort A patients had a mean (SD) age of 68.5 (9.5) years, PD duration of 12.1 (5.3) years, and least squares mean (SE) OFF time of 5.2 (0.6) h at baseline. Patients on LDp/CDp showed statistically significant reductions (95